Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.74 is 44% below its 5-year average of -2.60, near the low end of its 5-year range (-3.74–-1.82).
36.25% below its 12-month average of -2.75.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.09.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:01:32.649Z. Historical observations retain their original dates. Historical series through 2015-11-06.
EARNINGS PER SHARE (EPS)
-3.74
EARNINGS PER SHARE (EPS) AVG TTM
-2.75
EARNINGS PER SHARE (EPS) AVG 3Y
-2.51
EARNINGS PER SHARE (EPS) AVG 5Y
-2.60
EARNINGS PER SHARE (EPS) AVG 10Y
-5.05
EARNINGS PER SHARE (EPS) AVG 15Y
-4.06
EARNINGS PER SHARE (EPS) AVG 20Y
-3.36
CURRENT VS TTM AVG
-36.25%
CURRENT VS 3Y AVG
-48.86%
CURRENT VS 5Y AVG
-43.66%
CURRENT VS 10Y AVG
+25.94%
CURRENT VS 15Y AVG
+7.85%
CURRENT VS 20Y AVG
-11.26%
EyePoint Pharmaceuticals, Inc.
Market Cap
$264.94M
Earnings Per Share (EPS)
-3.74
TTM Avg
-2.75
3Y Avg
-2.51
5Y Avg
-2.60
Market Cap
$265.39M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.82
3Y Avg
-2.37
5Y Avg
-2.68
Market Cap
$264.10M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.90
3Y Avg
-0.84
5Y Avg
-0.86
Market Cap
$263.44M
Earnings Per Share (EPS)
-1.15
TTM Avg
-2.48
3Y Avg
-2.45
5Y Avg
-2.00
Market Cap
$266.63M
Earnings Per Share (EPS)
-0.93
TTM Avg
-0.92
3Y Avg
-0.85
5Y Avg
-0.65
Market Cap
$261.89M
Earnings Per Share (EPS)
-1.20
TTM Avg
-3.73
3Y Avg
-17.53
5Y Avg
-47.09
Market Cap
$261.62M
Earnings Per Share (EPS)
-0.69
TTM Avg
-0.60
3Y Avg
-0.18
5Y Avg
-0.21
Market Cap
$261.24M
Earnings Per Share (EPS)
-0.53
TTM Avg
-5.25
3Y Avg
-13.51
5Y Avg
-397.38
Market Cap
$270.23M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| EyePoint Pharmaceuticals, Inc. (EYPT) | $264.94M | -3.74 | -2.75 | -2.51 | -2.60 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $265.39M | -0.48 | -0.82 | -2.37 | -2.68 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.10M | -0.99 | -0.90 | -0.84 | -0.86 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $263.44M | -1.15 | -2.48 | -2.45 | -2.00 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $266.63M | -0.93 | -0.92 | -0.85 | -0.65 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.89M | -1.20 | -3.73 | -17.53 | -47.09 |
| OraSure Technologies, Inc. (OSUR)vs › | $261.62M | -0.69 | -0.60 | -0.18 | -0.21 |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | -0.53 | -5.25 | -13.51 | -397.38 |
| Scribe Therapeutics Inc. (SCTX)vs › | $270.23M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.26M | -0.86 | -1.73 | -3.85 | -2.38 |
Trailing EPS (TTM)
$-3.74
Forward EPS (Est.)
$-3.72
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.17 |
| 2024-12-31 | -2.32 |
| 2023-12-31 | -1.82 |
| 2022-12-31 | -2.74 |
| 2021-12-31 | -2.03 |
| 2020-12-31 | -3.54 |
| 2019-12-31 | -5.44 |
| 2018-06-30 | -12.71 |
| 2017-06-30 | -11.50 |
| 2016-06-30 | -5.23 |
| 2015-06-30 | -6.81 |
| 2014-06-30 | 2.20 |
| 2013-06-30 | -5.16 |
| 2012-06-30 | -5.20 |
| 2011-06-30 | -11.95 |
| 2010-06-30 | -4.40 |
| 2009-06-30 | 4.80 |
| 2008-06-30 | -1.40 |
| 2004-06-30 | -23.70 |
| 2003-06-30 | -1.35 |
| 2002-06-30 | -0.05 |
| 2002-06-30 | -0.55 |
